Status:
COMPLETED
Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of the study is to assess the safety and efficacy of ABT-874 in the treatment of moderate to severe chronic plaque psoriasis.
Eligibility Criteria
Inclusion
- Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.
- Subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate to severe plaque psoriasis
Exclusion
- Subject had previously received systemic or biologic anti-IL-12 therapy
- Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid UVB or PUVA phototherapy
- Subject is taking or requires oral or injectable corticosteroids
- Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
- Female subject who is pregnant or breast-feeding or considering becoming pregnant
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT00292396
Start Date
November 1 2005
End Date
April 1 2008
Last Update
January 18 2013
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Reference ID/Investigator# 3351
San Diego, California, United States, 92123
2
Site Reference ID/Investigator# 3347
Alpharetta, Georgia, United States, 30022
3
Site Reference ID/Investigator# 3348
Skokie, Illinois, United States, 60077
4
Site Reference ID/Investigator# 993
Indianapolis, Indiana, United States, 46256